Trial Profile
A Phase III, Multicenter, Placebo-controlled, Randomized, Double-blind Durability and Retreatment Study to Evaluate the Safety and Efficacy of PROCHYMAL (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Maintenance and Re-induction of Clinical Benefit and Remission in Subjects Experiencing Treatment-refractory Moderate-to-severe Crohn's Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Apr 2020
Price :
$35
*
At a glance
- Drugs Remestemcel-L (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Sponsors Mesoblast
- 20 May 2014 New trial record
- 16 Nov 2009
- 28 Mar 2009